279 related articles for article (PubMed ID: 24150765)
1. Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel.
Chen F; Ouyang Y; Ye T; Ni B; Chen A
J Cell Biochem; 2014 Apr; 115(4):651-8. PubMed ID: 24150765
[TBL] [Abstract][Full Text] [Related]
2. Regulation of TRPV5 transcription and expression by E2/ERα signalling contributes to inhibition of osteoclastogenesis.
Song T; Lin T; Ma J; Guo L; Zhang L; Zhou X; Ye T
J Cell Mol Med; 2018 Oct; 22(10):4738-4750. PubMed ID: 30063124
[TBL] [Abstract][Full Text] [Related]
3. Knockout of TRPV6 causes osteopenia in mice by increasing osteoclastic differentiation and activity.
Chen F; Ni B; Yang YO; Ye T; Chen A
Cell Physiol Biochem; 2014; 33(3):796-809. PubMed ID: 24686448
[TBL] [Abstract][Full Text] [Related]
4. The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption.
van der Eerden BC; Hoenderop JG; de Vries TJ; Schoenmaker T; Buurman CJ; Uitterlinden AG; Pols HA; Bindels RJ; van Leeuwen JP
Proc Natl Acad Sci U S A; 2005 Nov; 102(48):17507-12. PubMed ID: 16291808
[TBL] [Abstract][Full Text] [Related]
5. The calcium channel TRPV6 is a novel regulator of RANKL-induced osteoclastic differentiation and bone absorption activity through the IGF-PI3K-AKT pathway.
Ma J; Zhu L; Zhou Z; Song T; Yang L; Yan X; Chen A; Ye TW
Cell Prolif; 2021 Jan; 54(1):e12955. PubMed ID: 33159483
[TBL] [Abstract][Full Text] [Related]
6. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
[TBL] [Abstract][Full Text] [Related]
7. [Zoledronate inhibits TRPV5 and NFATc1 expression during differentiation of osteoclasts].
Lin J; Dong W; Zhang P; Li P; Sun H; Qi M
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Aug; 34(9):1254-8. PubMed ID: 25263354
[TBL] [Abstract][Full Text] [Related]
8. Afamin stimulates osteoclastogenesis and bone resorption via Gi-coupled receptor and Ca2+/calmodulin-dependent protein kinase (CaMK) pathways.
Kim BJ; Lee YS; Lee SY; Park SY; Dieplinger H; Yea K; Lee SH; Koh JM; Kim GS
J Endocrinol Invest; 2013 Nov; 36(10):876-82. PubMed ID: 23698732
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
10. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts.
Kanno S; Hirano S; Kayama F
Toxicology; 2004 Oct; 203(1-3):211-20. PubMed ID: 15363596
[TBL] [Abstract][Full Text] [Related]
11. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss.
Guan H; Zhao L; Cao H; Chen A; Xiao J
FASEB J; 2015 Mar; 29(3):1092-101. PubMed ID: 25466887
[TBL] [Abstract][Full Text] [Related]
12. Heparin inhibits osteoclastic differentiation and function.
Ariyoshi W; Takahashi T; Kanno T; Ichimiya H; Shinmyouzu K; Takano H; Koseki T; Nishihara T
J Cell Biochem; 2008 Apr; 103(6):1707-17. PubMed ID: 18231993
[TBL] [Abstract][Full Text] [Related]
13. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
Idris AI; Landao-Bassonga E; Ralston SH
Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
[TBL] [Abstract][Full Text] [Related]
14. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
15. Herba epimedii flavonoids suppress osteoclastic differentiation and bone resorption by inducing G2/M arrest and apoptosis.
Zhang D; Zhang J; Fong C; Yao X; Yang M
Biochimie; 2012 Dec; 94(12):2514-22. PubMed ID: 22796380
[TBL] [Abstract][Full Text] [Related]
16. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARγ and APC.
Guo L; Chen K; Yuan J; Huang P; Xu X; Li C; Qian N; Qi J; Shao Z; Deng L; He C; Xu J
J Cell Physiol; 2018 Jan; 234(1):581-594. PubMed ID: 30272823
[TBL] [Abstract][Full Text] [Related]
17. RANKL-induced TRPV2 expression regulates osteoclastogenesis via calcium oscillations.
Kajiya H; Okamoto F; Nemoto T; Kimachi K; Toh-Goto K; Nakayana S; Okabe K
Cell Calcium; 2010 Nov; 48(5):260-9. PubMed ID: 20980052
[TBL] [Abstract][Full Text] [Related]
18. IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
Kitami S; Tanaka H; Kawato T; Tanabe N; Katono-Tani T; Zhang F; Suzuki N; Yonehara Y; Maeno M
Biochimie; 2010 Apr; 92(4):398-404. PubMed ID: 20045440
[TBL] [Abstract][Full Text] [Related]
19. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
[TBL] [Abstract][Full Text] [Related]
20. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression.
Goto H; Hozumi A; Osaki M; Fukushima T; Sakamoto K; Yonekura A; Tomita M; Furukawa K; Shindo H; Baba H
Cytokine; 2011 Dec; 56(3):662-8. PubMed ID: 21963155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
